Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

Party season approaches; but first, conferences.

Syndax scored the first menin approval, but Kura is first with a licensing deal.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

Kura will see more combo data, while a new contender from Sumitomo emerges.